Triple inhaled therapy for maintenance of chronic obstructive pulmonary disease (COPD) consists of an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta2-agonist. Recent clinical studies evaluating triple therapy found a reduction in COPD exacerbations compared with other combination therapies. This article discusses the role of triple therapy in treating patients with COPD.